230 related articles for article (PubMed ID: 15122310)
1. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects.
Thall PF; Champlin RE; Andersson BS
Bone Marrow Transplant; 2004 Jun; 33(12):1191-9. PubMed ID: 15122310
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
[TBL] [Abstract][Full Text] [Related]
3. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
[TBL] [Abstract][Full Text] [Related]
5. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
6. Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide.
Saikia TK; Advani SH; Parikh PM; Bapna A; Somjee S; Mukhopadhyay A; Gopal R; Nair CN
J Assoc Physicians India; 1999 Aug; 47(8):770-3. PubMed ID: 10778619
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
[TBL] [Abstract][Full Text] [Related]
8. Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia.
Urban C; Schwinger W; Slavc I; Schmid C; Gamillscheg A; Lackner H; Hauer C; Pakisch B
Bone Marrow Transplant; 1990 May; 5(5):353-6. PubMed ID: 2190661
[TBL] [Abstract][Full Text] [Related]
9. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
[TBL] [Abstract][Full Text] [Related]
10. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
Gaziev D; Galimberti M; Polchi P; Angelucci E; Giardini C; Baronciani D; Andreani M; Persini B; Erer B; Sodani P; Manna M; Nicolini G; Visani G; Lucarelli G;
Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
[TBL] [Abstract][Full Text] [Related]
11. Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia.
Copelan EA; Crilley PA; Szer J; Dodds AJ; Stevenson D; Phillips G; Elder P; Nivison-Smith I; Avalos BR; Penza S; Topolsky D; Sobecks R; Kalaycio M; Bolwell BJ
Biol Blood Marrow Transplant; 2009 Jul; 15(7):851-5. PubMed ID: 19539217
[TBL] [Abstract][Full Text] [Related]
12. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
[TBL] [Abstract][Full Text] [Related]
13. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
14. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
15. Relapse of chronic myeloid leukemia (CML) in lymphoid crisis after allogeneic bone marrow transplantation for CML in chronic phase with busulfan plus cyclophosphamide regimen.
Takami A; Chuhjo T; Nakao S
Haematologica; 2002 Jun; 87(6):659-61. PubMed ID: 12031925
[No Abstract] [Full Text] [Related]
16. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
[TBL] [Abstract][Full Text] [Related]
17. The development of busulfan/cyclophosphamide preparative regimens.
Santos GW
Semin Oncol; 1993 Aug; 20(4 Suppl 4):12-6; quiz 17. PubMed ID: 8342070
[TBL] [Abstract][Full Text] [Related]
18. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
19. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan.
Kim SE; Lee JH; Choi SJ; Lee JH; Ryu SG; Lee KH
Haematologica; 2005 Feb; 90(2):285-6. PubMed ID: 15710597
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide.
Avalos BR; Klein JL; Kapoor N; Copelan EA
Bone Marrow Transplant; 1993 Dec; 12(6):655-8. PubMed ID: 8136749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
